Abstract
Recent findings indicate that Epstein-Barr virus (EBV)-infected T-/natural killer (NK) cells play an important role in the pathogenesis of mosquito allergy, and most patients with mosquito allergy die early in life if not properly treated. Over the last 7 years, we have been using combination chemotherapy and allogeneic stem cell transplantation for the treatment of EBV-associated T-/NK cell lymphoproliferative disease (LPD) in which chronic active EBV infection and mosquito allergy were included. As of this writing, we have successfully treated 2 patients with mosquito allergy with chemotherapy in which EBV-infected T-/NK cells were eradicated. The findings suggest the possible role of chemotherapy in the treatment of EBV-associated T-/NK cell LPD.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Child
-
Culicidae*
-
Epstein-Barr Virus Infections / complications
-
Epstein-Barr Virus Infections / pathology
-
Epstein-Barr Virus Infections / therapy*
-
Female
-
Humans
-
Hypersensitivity, Immediate / complications
-
Hypersensitivity, Immediate / pathology
-
Hypersensitivity, Immediate / therapy*
-
Insect Bites and Stings / complications
-
Insect Bites and Stings / pathology
-
Insect Bites and Stings / therapy*
-
Killer Cells, Natural* / pathology
-
Killer Cells, Natural* / virology
-
Lymphoproliferative Disorders / complications
-
Lymphoproliferative Disorders / pathology
-
Lymphoproliferative Disorders / therapy*
-
Male
-
Remission Induction / methods
-
Stem Cell Transplantation / methods
-
T-Lymphocytes* / pathology
-
T-Lymphocytes* / virology
-
Transplantation, Homologous